메뉴 건너뛰기




Volumn 17, Issue 10, 2009, Pages 1821-1829

The endocannabinoid system: Potential for reducing cardiometabolic risk

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID RECEPTOR; ENDOCANNABINOID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

EID: 70349488868     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.107     Document Type: Review
Times cited : (8)

References (95)
  • 1
    • 0032162184 scopus 로고    scopus 로고
    • Evaluation, and treatment of overweight and obesity in adults - the evidence report
    • Clinical Guidelines on the Identification National Institutes of Health. National Institutes of Health
    • Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. National Institutes of Health. Obes Res 1998;6(Suppl 2):51S-209S.
    • (1998) Obes Res , vol.6 , Issue.SUPPL 2
  • 2
    • 0028959193 scopus 로고
    • Changes in energy expenditure resulting from altered body weight
    • Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332:621-628.
    • (1995) N Engl J Med , vol.332 , pp. 621-628
    • Leibel, R.L.1    Rosenbaum, M.2    Hirsch, J.3
  • 3
    • 0038650880 scopus 로고    scopus 로고
    • Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects
    • Rosenbaum M, Vandenborne K, Goldsmith R et al. Effects of experimental weight perturbation on skeletal muscle work efficiency in human subjects. Am J Physiol Regul Integr Comp Physiol 2003;285:R183-R192.
    • (2003) Am J Physiol Regul Integr Comp Physiol , vol.285
    • Rosenbaum, M.1    Vandenborne, K.2    Goldsmith, R.3
  • 4
    • 35648968069 scopus 로고    scopus 로고
    • The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms
    • Gong Y, Ishida-Takahashi R, Villanueva EC et al. The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms. J Biol Chem 2007;282:31019-31027.
    • (2007) J Biol Chem , vol.282 , pp. 31019-31027
    • Gong, Y.1    Ishida-Takahashi, R.2    Villanueva, E.C.3
  • 7
    • 43049094858 scopus 로고    scopus 로고
    • Role of the endocannabinoid system in energy balance regulation and obesity
    • Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. Front Horm Res 2008;36:135-145.
    • (2008) Front Horm Res , vol.36 , pp. 135-145
    • Cota, D.1
  • 8
    • 33846439476 scopus 로고    scopus 로고
    • Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors
    • Pi-Sunyer FX. Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. Obesity (Silver Spring) 2006;14(Suppl 3):135S-142S.
    • (2006) Obesity (Silver Spring) , vol.14 , Issue.SUPPL 3
    • Pi-Sunyer, F.X.1
  • 10
    • 48149101434 scopus 로고    scopus 로고
    • The endocannabinoid system in obesity and type 2 diabetes
    • Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008;51:1356-1367.
    • (2008) Diabetologia , vol.51 , pp. 1356-1367
    • Di Marzo, V.1
  • 11
    • 0027078685 scopus 로고
    • Isolation and structure of a brain constituent that binds to the cannabinoid receptor
    • Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
    • (1992) Science , vol.258 , pp. 1946-1949
    • Devane, W.A.1    Hanus, L.2    Breuer, A.3
  • 12
    • 0028970517 scopus 로고
    • 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain
    • Sugiura T, Kondo S, Sukagawa A et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215:89-97.
    • (1995) Biochem Biophys Res Commun , vol.215 , pp. 89-97
    • Sugiura, T.1    Kondo, S.2    Sukagawa, A.3
  • 13
    • 48249097797 scopus 로고    scopus 로고
    • Endocannabinoids: Synthesis and degradation
    • Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008;160:1-24.
    • (2008) Rev Physiol Biochem Pharmacol , vol.160 , pp. 1-24
    • Di Marzo, V.1
  • 14
    • 54049149312 scopus 로고    scopus 로고
    • Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown
    • Placzek EA, Okamoto Y, Ueda N, Barker EL. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. Neuropharmacology 2008;55:1095-1104.
    • (2008) Neuropharmacology , vol.55 , pp. 1095-1104
    • Placzek, E.A.1    Okamoto, Y.2    Ueda, N.3    Barker, E.L.4
  • 15
    • 0033614020 scopus 로고    scopus 로고
    • Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds
    • Sugiura T, Kodaka T, Nakane S et al. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J Biol Chem 1999;274:2794-2801.
    • (1999) J Biol Chem , vol.274 , pp. 2794-2801
    • Sugiura, T.1    Kodaka, T.2    Nakane, S.3
  • 16
    • 38049117749 scopus 로고    scopus 로고
    • Hemopressin is an inverse agonist of CB1 cannabinoid receptors
    • Heimann AS, Gomes I, Dale CS et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 2007;104:20588-20593.
    • (2007) Proc Natl Acad Sci USA , vol.104 , pp. 20588-20593
    • Heimann, A.S.1    Gomes, I.2    Dale, C.S.3
  • 17
    • 45849112141 scopus 로고    scopus 로고
    • Endocannabinoids and liver disease. i V. Endocannabinoid involvement in obesity and hepatic steatosis
    • Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. I V. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2008;294:G1101-G1104.
    • (2008) Am J Physiol Gastrointest Liver Physiol , vol.294
    • Kunos, G.1    Osei-Hyiaman, D.2
  • 18
    • 48749103773 scopus 로고    scopus 로고
    • Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review
    • Svízenská I, Dubový P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review. Pharmacol Biochem Behav 2008;90:501-511.
    • (2008) Pharmacol Biochem Behav , vol.90 , pp. 501-511
    • Svízenská, I.1    Dubový, P.2    Sulcová, A.3
  • 19
    • 29544435299 scopus 로고    scopus 로고
    • Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell
    • Juan-Picó P, Fuentes E, Bermúdez-Silva FJ et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 2006;39:155-162.
    • (2006) Cell Calcium , Issue.39 , pp. 155-162
    • Juan-Picó, P.1    Fuentes, E.2    Bermúdez-Silva, F.J.3
  • 20
    • 18844400058 scopus 로고    scopus 로고
    • Cannabinoid-based drugs as anti-inflammatory therapeutics
    • Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400-411.
    • (2005) Nat Rev Immunol , vol.5 , pp. 400-411
    • Klein, T.W.1
  • 21
    • 65249119361 scopus 로고    scopus 로고
    • Lipid mediators in health and disease: Enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation
    • Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009;49:123-150.
    • (2009) Annu Rev Pharmacol Toxicol , vol.49 , pp. 123-150
    • Shimizu, T.1
  • 22
    • 33847702499 scopus 로고    scopus 로고
    • Critical enzymes involved in endocannabinoid metabolism
    • Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett 2007;14:237-246.
    • (2007) Protein Pept Lett , vol.14 , pp. 237-246
    • Basavarajappa, B.S.1
  • 24
    • 33644934527 scopus 로고    scopus 로고
    • The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum
    • Kawamura Y, Fukaya M, Maejima T et al. The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 2006;26:2991-3001.
    • (2006) J Neurosci , vol.26 , pp. 2991-3001
    • Kawamura, Y.1    Fukaya, M.2    Maejima, T.3
  • 25
    • 34249898186 scopus 로고    scopus 로고
    • Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration
    • Tasker JG. Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration. Obesity (Silver Spring) 2006;14(Suppl 5):259S-265S.
    • (2006) Obesity (Silver Spring) , vol.14 , Issue.SUPPL 5
    • Tasker, J.G.1
  • 26
    • 0035984946 scopus 로고    scopus 로고
    • Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol
    • Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-557.
    • (2002) Br J Pharmacol , vol.136 , pp. 550-557
    • Kirkham, T.C.1    Williams, C.M.2    Fezza, F.3    Di Marzo, V.4
  • 27
    • 0032541111 scopus 로고    scopus 로고
    • Appetite suppression and weight loss after the cannabinoid antagonist SR 141716
    • Colombo G, Agabio R, Diaz G et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998;63:PL113-PL117.
    • (1998) Life Sci , vol.63
    • Colombo, G.1    Agabio, R.2    Diaz, G.3
  • 28
    • 0035848818 scopus 로고    scopus 로고
    • Leptin-regulated endocannabinoids are involved in maintaining food intake
    • Di Marzo V, Goparaju SK, Wang L et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825.
    • (2001) Nature , vol.410 , pp. 822-825
    • Di Marzo, V.1    Goparaju, S.K.2    Wang, L.3
  • 29
    • 20944436157 scopus 로고    scopus 로고
    • Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
    • Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
    • (2005) J Clin Invest , vol.115 , pp. 1298-1305
    • Osei-Hyiaman, D.1    Depetrillo, M.2    Pacher, P.3
  • 30
    • 33746110406 scopus 로고    scopus 로고
    • Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-- LH 21
    • Pavon FJ, Bilbao A, Hernández-Folgado L et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Neuropharmacology 2006;51:358-366.
    • (2006) Neuropharmacology , vol.51 , pp. 358-366
    • Pavon, F.J.1    Bilbao, A.2    Hernández-Folgado, L.3
  • 31
    • 34547423962 scopus 로고    scopus 로고
    • Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
    • Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46:122-129.
    • (2007) Hepatology , vol.46 , pp. 122-129
    • Gary-Bobo, M.1    Elachouri, G.2    Gallas, J.F.3
  • 32
    • 0037374766 scopus 로고    scopus 로고
    • The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
    • Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-914.
    • (2003) Mol Pharmacol , vol.63 , pp. 908-914
    • Bensaid, M.1    Gary-Bobo, M.2    Esclangon, A.3
  • 33
    • 21244434879 scopus 로고    scopus 로고
    • CB1 cannabinoid receptor-mediated modulation of food intake in mice
    • Wiley JL, Burston JJ, Leggett DC et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145:293-300.
    • (2005) Br J Pharmacol , vol.145 , pp. 293-300
    • Wiley, J.L.1    Burston, J.J.2    Leggett, D.C.3
  • 34
    • 43449127219 scopus 로고    scopus 로고
    • The endocannabinoid system in brain reward processes
    • Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol 2008;154: 369-383.
    • (2008) Br J Pharmacol , vol.154 , pp. 369-383
    • Solinas, M.1    Goldberg, S.R.2    Piomelli, D.3
  • 35
    • 34347336422 scopus 로고    scopus 로고
    • Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions
    • Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007;91:383-388.
    • (2007) Physiol Behav , vol.91 , pp. 383-388
    • Salamone, J.D.1    McLaughlin, P.J.2    Sink, K.3    Makriyannis, A.4    Parker, L.A.5
  • 36
    • 0345791451 scopus 로고    scopus 로고
    • Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats
    • Verty AN, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004;354: 217-220.
    • (2004) Neurosci Lett , vol.354 , pp. 217-220
    • Verty, A.N.1    McGregor, I.S.2    Mallet, P.E.3
  • 37
    • 50649106505 scopus 로고    scopus 로고
    • Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats
    • Mathes CM, Ferrara M, Rowland NE. Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats. Am J Physiol Regul Integr Comp Physiol 2008;295:R67-R75.
    • (2008) Am J Physiol Regul Integr Comp Physiol , vol.295
    • Mathes, C.M.1    Ferrara, M.2    Rowland, N.E.3
  • 38
    • 34248551106 scopus 로고    scopus 로고
    • The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extracellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food
    • Melis T, Succu S, Sanna F et al. The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extracellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007;419:231-235.
    • (2007) Neurosci Lett , vol.419 , pp. 231-235
    • Melis, T.1    Succu, S.2    Sanna, F.3
  • 39
    • 55749101589 scopus 로고    scopus 로고
    • Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats
    • DiPatrizio NV, Simansky KJ. Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 2008;28:9702-9709.
    • (2008) J Neurosci , vol.28 , pp. 9702-9709
    • Dipatrizio, N.V.1    Simansky, K.J.2
  • 40
    • 57349122335 scopus 로고    scopus 로고
    • Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors
    • Dipatrizio N V, Simansky KJ. Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. Am J Physiol Regul Integr Comp Physiol 2008;295:R1409-R1414.
    • (2008) Am J Physiol Regul Integr Comp Physiol , vol.295
    • Dipatrizio, N.V.1    Simansky, K.J.2
  • 41
    • 85047690626 scopus 로고    scopus 로고
    • The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
    • Cota D, Marsicano G, Tschöp M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
    • (2003) J Clin Invest , vol.112 , pp. 423-431
    • Cota, D.1    Marsicano, G.2    Tschöp, M.3
  • 42
    • 1842866963 scopus 로고    scopus 로고
    • CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
    • Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28:640-648.
    • (2004) Int J Obes Relat Metab Disord , vol.28 , pp. 640-648
    • Ravinet Trillou, C.1    Delgorge, C.2    Menet, C.3    Arnone, M.4    Soubrié, P.5
  • 43
    • 33746490030 scopus 로고    scopus 로고
    • The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake
    • Thornton-Jones ZD, Kennett GA, Benwell KR et al. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 2006;84:353-359.
    • (2006) Pharmacol Biochem Behav , vol.84 , pp. 353-359
    • Thornton-Jones, Z.D.1    Kennett, G.A.2    Benwell, K.R.3
  • 44
    • 0038070321 scopus 로고    scopus 로고
    • Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats
    • Vickers S P, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003;167:103-111.
    • (2003) Psychopharmacology (Berl) , vol.167 , pp. 103-111
    • Vickers, S.P.1    Webster, L.J.2    Wyatt, A.3    Dourish, C.T.4    Kennett, G.A.5
  • 45
    • 33747644061 scopus 로고    scopus 로고
    • Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia
    • Matias I, Gonthier M P, Orlando P et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 3171-3180
    • Matias, I.1    Gonthier, M.P.2    Orlando, P.3
  • 46
    • 53049086988 scopus 로고    scopus 로고
    • Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications
    • Viveros M P, de Fonseca FR, Bermudez-Silva FJ, McPartland JM. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 2008;8:220-230.
    • (2008) Endocr Metab Immune Disord Drug Targets , vol.8 , pp. 220-230
    • Viveros, M.P.1    De Fonseca, F.R.2    Bermudez-Silva, F.J.3    McPartland, J.M.4
  • 47
    • 1642298863 scopus 로고    scopus 로고
    • Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin
    • Burdyga G, Lal S, Varro A et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004;24:2708-2715.
    • (2004) J Neurosci , vol.24 , pp. 2708-2715
    • Burdyga, G.1    Lal, S.2    Varro, A.3
  • 48
    • 0037162116 scopus 로고    scopus 로고
    • Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery
    • Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-1630.
    • (2002) N Engl J Med , vol.346 , pp. 1623-1630
    • Cummings, D.E.1    Weigle, D.S.2    Frayo, R.S.3
  • 49
    • 45549092924 scopus 로고    scopus 로고
    • The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system
    • Kola B, Farkas I, Christ-Crain M et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 2008;3:e1797.
    • (2008) PLoS ONE , vol.3
    • Kola, B.1    Farkas, I.2    Christ-Crain, M.3
  • 50
    • 8744249918 scopus 로고    scopus 로고
    • The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
    • Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004;143:520-523.
    • (2004) Br J Pharmacol , vol.143 , pp. 520-523
    • Tucci, S.A.1    Rogers, E.K.2    Korbonits, M.3    Kirkham, T.C.4
  • 51
    • 31044456243 scopus 로고    scopus 로고
    • The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes
    • Gary-Bobo M, Elachouri G, Scatton B et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006;69:471-478.
    • (2006) Mol Pharmacol , vol.69 , pp. 471-478
    • Gary-Bobo, M.1    Elachouri, G.2    Scatton, B.3
  • 52
    • 35348961244 scopus 로고    scopus 로고
    • The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms
    • Pagano C, Pilon C, Calcagno A et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92:4810-4819.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 4810-4819
    • Pagano, C.1    Pilon, C.2    Calcagno, A.3
  • 53
    • 42449097191 scopus 로고    scopus 로고
    • Endocannabinoids, adipose tissue and lipid metabolism
    • Pagano C, Rossato M, Vettor R. Endocannabinoids, adipose tissue and lipid metabolism. J Neuroendocrinol 2008;20(Suppl 1):124-129.
    • (2008) J Neuroendocrinol , vol.20 , Issue.SUPPL 1 , pp. 124-129
    • Pagano, C.1    Rossato, M.2    Vettor, R.3
  • 54
    • 24644500204 scopus 로고    scopus 로고
    • The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance
    • Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005;19: 1567-1569.
    • (2005) FASEB J , vol.19 , pp. 1567-1569
    • Jbilo, O.1    Ravinet-Trillou, C.2    Arnone, M.3
  • 55
    • 43449091899 scopus 로고    scopus 로고
    • Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats
    • Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J Obes (Lond) 2008;32:863-870.
    • (2008) Int J Obes (Lond) , vol.32 , pp. 863-870
    • Kunz, I.1    Meier, M.K.2    Bourson, A.3    Fisseha, M.4    Schilling, W.5
  • 56
    • 37449007904 scopus 로고    scopus 로고
    • The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake
    • Addy C, Wright H, Van Laere K et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78.
    • (2008) Cell Metab , vol.7 , pp. 68-78
    • Addy, C.1    Wright, H.2    Van Laere, K.3
  • 57
    • 33947606528 scopus 로고    scopus 로고
    • Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men
    • Côté M, Matias I, Lemieux I et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31: 692-699.
    • (2007) Int J Obes (Lond) , vol.31 , pp. 692-699
    • Côté, M.1    Matias, I.2    Lemieux, I.3
  • 58
    • 58149471799 scopus 로고    scopus 로고
    • Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors
    • Di Marzo V, Côté M, Matias I et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52:213-217.
    • (2009) Diabetologia , vol.52 , pp. 213-217
    • Di Marzo, V.1    Côté, M.2    Matias, I.3
  • 59
    • 25844460609 scopus 로고    scopus 로고
    • Activation of the peripheral endocannabinoid system in human obesity
    • Engeli S, Böhnke J, Feldpausch M et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-2843.
    • (2005) Diabetes , vol.54 , pp. 2838-2843
    • Engeli, S.1    Böhnke, J.2    Feldpausch, M.3
  • 60
    • 17844411014 scopus 로고    scopus 로고
    • Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
    • Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005;29:755-759.
    • (2005) Int J Obes (Lond) , vol.29 , pp. 755-759
    • Sipe, J.C.1    Waalen, J.2    Gerber, A.3    Beutler, E.4
  • 61
    • 34247874502 scopus 로고    scopus 로고
    • The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites
    • Jensen D P, Andreasen CH, Andersen MK et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J Mol Med 2007;85:445-449.
    • (2007) J Mol Med , vol.85 , pp. 445-449
    • Jensen, D.P.1    Andreasen, C.H.2    Andersen, M.K.3
  • 62
    • 34347273447 scopus 로고    scopus 로고
    • Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men
    • Russo P, Strazzullo P, Cappuccio FP et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab 2007;92:2382-2386.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 2382-2386
    • Russo, P.1    Strazzullo, P.2    Cappuccio, F.P.3
  • 63
    • 19344363569 scopus 로고    scopus 로고
    • Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa
    • Monteleone P, Matias I, Martiadis V et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005;30:1216-1221.
    • (2005) Neuropsychopharmacology , vol.30 , pp. 1216-1221
    • Monteleone, P.1    Matias, I.2    Martiadis, V.3
  • 64
    • 45849112141 scopus 로고    scopus 로고
    • Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis
    • Kunos G, Osei-Hyiaman D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2008;294:G1101-G1104.
    • (2008) Am J Physiol Gastrointest Liver Physiol , vol.294
    • Kunos, G.1    Osei-Hyiaman, D.2
  • 65
    • 38749134463 scopus 로고    scopus 로고
    • Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats
    • Muñoz-Luque J, Ros J, Fernández-Varo G et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008;324:475-483.
    • (2008) J Pharmacol Exp Ther , vol.324 , pp. 475-483
    • Muñoz-Luque, J.1    Ros, J.2    Fernández-Varo, G.3
  • 66
    • 38649114788 scopus 로고    scopus 로고
    • Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver
    • Jeong WI, Osei-Hyiaman D, Park O et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7:227-235.
    • (2008) Cell Metab , vol.7 , pp. 227-235
    • Jeong, W.I.1    Osei-Hyiaman, D.2    Park, O.3
  • 67
    • 51349153318 scopus 로고    scopus 로고
    • Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
    • Osei-Hyiaman D, Liu J, Zhou L et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169.
    • (2008) J Clin Invest , vol.118 , pp. 3160-3169
    • Osei-Hyiaman, D.1    Liu, J.2    Zhou, L.3
  • 69
    • 33846829811 scopus 로고    scopus 로고
    • Abdominal obesity: Role in the pathophysiology of metabolic disease and cardiovascular risk
    • discussion S29-S32
    • Bergman RN, Kim SP, Hsu IR et al. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med 2007;120(2 Suppl 1):S3-S8; discussion S29-S32.
    • (2007) Am J Med , vol.120 , Issue.2 SUPPL 1
    • Bergman, R.N.1    Kim, S.P.2    Hsu, I.R.3
  • 71
    • 13244249625 scopus 로고    scopus 로고
    • Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice
    • Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005;29:183-187.
    • (2005) Int J Obes (Lond) , vol.29 , pp. 183-187
    • Liu, Y.L.1    Connoley, I.P.2    Wilson, C.A.3    Stock, M.J.4
  • 72
    • 13244284806 scopus 로고    scopus 로고
    • Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome
    • Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-175.
    • (2005) J Intern Med , vol.257 , pp. 167-175
    • Trujillo, M.E.1    Scherer, P.E.2
  • 73
    • 0035663963 scopus 로고    scopus 로고
    • Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
    • Combs T P, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001;108: 1875-1881.
    • (2001) J Clin Invest , vol.108 , pp. 1875-1881
    • Combs, T.P.1    Berg, A.H.2    Obici, S.3    Scherer, P.E.4    Rossetti, L.5
  • 74
    • 12744260206 scopus 로고    scopus 로고
    • The anti-obesity effect of rimonabant is associated with an improved serum lipid profile
    • Poirier B, Bidouard J P, Cadrouvele C et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7:65-72.
    • (2005) Diabetes Obes Metab , vol.7 , pp. 65-72
    • Poirier, B.1    Bidouard, J.P.2    Cadrouvele, C.3
  • 75
    • 34147132963 scopus 로고    scopus 로고
    • Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level
    • Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007;92:1555-1559.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 1555-1559
    • Lofgren, P.1    Sjolin, E.2    Wahlen, K.3    Hoffstedt, J.4
  • 76
    • 59449098696 scopus 로고    scopus 로고
    • Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways
    • Watanabe T, Kubota N, Ohsugi M et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 2009;284:1803-1812.
    • (2009) J Biol Chem , vol.284 , pp. 1803-1812
    • Watanabe, T.1    Kubota, N.2    Ohsugi, M.3
  • 77
    • 15444362306 scopus 로고    scopus 로고
    • Rimonabant - a selective CB1 antagonist
    • Boyd ST, Fremming BA. Rimonabant - a selective CB1 antagonist. Ann Pharmacother 2005;39:684-690.
    • (2005) Ann Pharmacother , vol.39 , pp. 684-690
    • Boyd, S.T.1    Fremming, B.A.2
  • 78
    • 32644441249 scopus 로고    scopus 로고
    • Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial
    • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-775.
    • (2006) JAMA , vol.295 , pp. 761-775
    • Pi-Sunyer, F.X.1    Aronne, L.J.2    Heshmati, H.M.3    Devin, J.4    Rosenstock, J.5
  • 79
    • 27844463517 scopus 로고    scopus 로고
    • Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
    • Després J P, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
    • (2005) N Engl J Med , vol.353 , pp. 2121-2134
    • Després, J.P.1    Golay, A.2    Sjöström, L.3
  • 80
    • 33751001942 scopus 로고    scopus 로고
    • Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study
    • Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal L F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672.
    • (2006) Lancet , vol.368 , pp. 1660-1672
    • Scheen, A.J.1    Finer, N.2    Hollander, P.3    Jensen, M.D.4    Van Gaal, L.F.5
  • 81
    • 17144382751 scopus 로고    scopus 로고
    • Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study
    • DOI 10.1016/S0140-6736(05)66374-X
    • Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397. (Pubitemid 40523733)
    • (2005) Lancet , vol.365 , Issue.9468 , pp. 1389-1397
    • Van Gaal, L.F.1    Rissanen, A.M.2    Scheen, A.J.3    Ziegler, O.4    Rossner, S.5
  • 82
    • 33748344924 scopus 로고    scopus 로고
    • Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks
    • Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006;114:974-984.
    • (2006) Circulation , vol.114 , pp. 974-984
    • Gadde, K.M.1    Allison, D.B.2
  • 83
    • 41149130137 scopus 로고    scopus 로고
    • Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/ obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
    • Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/ obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008;31(Suppl 2):S229-S240.
    • (2008) Diabetes Care , vol.31 , Issue.SUPPL 2
    • Van Gaal, L.1    Pi-Sunyer, X.2    Després, J.P.3    McCarthy, C.4    Scheen, A.5
  • 84
    • 0033251732 scopus 로고    scopus 로고
    • Etiology and pathogenesis of obesity
    • Bray GA. Etiology and pathogenesis of obesity. Clin Cornerstone 1999;2:1-15.
    • (1999) Clin Cornerstone , vol.2 , pp. 1-15
    • Bray, G.A.1
  • 85
    • 21644468930 scopus 로고    scopus 로고
    • The endocannabinoid system: A new therapeutic target for cardiovascular risk factor management
    • Finer N, Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 2005;5:121-124.
    • (2005) Br J Diabetes Vasc Dis , vol.5 , pp. 121-124
    • Finer, N.1    Pagotto, U.2
  • 86
    • 70349494119 scopus 로고    scopus 로고
    • Food and Drug Administration. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant) tablets, 20 mg. Sanofi Aventis. Advisory Committee, 13 June 2007 Accessed 9 August 2007
    • Food and Drug Administration. FDA Briefing Document. NDA 21-888. Zimulti (rimonabant) tablets, 20 mg. Sanofi Aventis. Advisory Committee, 13 June 2007. http://www.fda. gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder. pdf. Accessed 9 August 2007.
  • 88
    • 55849133067 scopus 로고    scopus 로고
    • Effects of taranabant, a novel cannabinoid 1 receptor (CB-1R) inverse agonist, on weight reduction in obese patients over 12 weeks
    • Carr R, Erondu N, Gonzalez C et al. Effects of taranabant, a novel cannabinoid 1 receptor (CB-1R) inverse agonist, on weight reduction in obese patients over 12 weeks. Atherosclerosis Suppl 2008;9:209.
    • (2008) Atherosclerosis Suppl , vol.9 , pp. 209
    • Carr, R.1    Erondu, N.2    Gonzalez, C.3
  • 89
    • 55849108537 scopus 로고    scopus 로고
    • A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results
    • Carr R, Gantz I, Erondu N et al. A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results. Atherosclerosis Suppl 2008;9:12.
    • (2008) Atherosclerosis Suppl , vol.9 , pp. 12
    • Carr, R.1    Gantz, I.2    Erondu, N.3
  • 90
    • 70349497214 scopus 로고    scopus 로고
    • European Medicines Agency recommends acomplia must not be used in patients on antidepressants or with major depression 21 July
    • European Medicines Agency recommends acomplia must not be used in patients on antidepressants or with major depression. Medical News Today, 21 July 2007. http://www.medicalnewstoday.com.
    • (2007) Medical News Today
  • 92
    • 57049102251 scopus 로고    scopus 로고
    • End of the line for cannabinoid receptor 1 as an anti-obesity target?
    • Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 2008;7:961-962.
    • (2008) Nat Rev Drug Discov , vol.7 , pp. 961-962
    • Jones, D.1
  • 93
    • 41649090426 scopus 로고    scopus 로고
    • Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial
    • Nissen SE, Nicholls SJ, Wolski K et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-1560.
    • (2008) JAMA , vol.299 , pp. 1547-1560
    • Nissen, S.E.1    Nicholls, S.J.2    Wolski, K.3
  • 94
    • 54849141400 scopus 로고    scopus 로고
    • Play an ADAGIO with a STRADIVARIUS: The right patient for CB1 receptor antagonists?
    • Di Marzo V. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists? Nat Clin Pract Cardiovasc Med 2008;5:610-612.
    • (2008) Nat Clin Pract Cardiovasc Med , vol.5 , pp. 610-612
    • Di Marzo, V.1
  • 95


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.